HEKMA vs. AQ Platform

HEKMA stands at the forefront of innovation, leveraging artificial intelligence to improve the effectiveness of clinical trials through enhanced patient recruitment, evaluation of trial feasibility, and improved patient engagement. Their all-encompassing platform serves a wide range of stakeholders, including contract research organizations (CROs), pharmaceutical companies, healthcare providers, and patients, by combining electronic health records (EHRs) with AI-enhanced trial matching, clinical trial management systems, and patient engagement tools. HEKMA's primary objective is to reduce enrollment delays, increase access to clinical trials—particularly for marginalized groups—and streamline the clinical research workflow to create a process that is more efficient, transparent, and focused on patient requirements. With a unique combination of healthcare expertise, artificial intelligence technology, and clinical operations knowledge, HEKMA ensures compliance with essential industry standards, such as HIPAA, 21 CFR Part 11, GDPR, and HL7/FHIR, maintaining the highest levels of regulatory adherence. By embracing cutting-edge technology, HEKMA aspires to revolutionize the clinical trial landscape, ultimately driving progress in medical research and enhancing patient outcomes. Their commitment to innovation not only addresses current challenges in clinical research but also positions them as leaders in shaping the future of healthcare.

The AQ Platform is a sophisticated software solution designed specifically for overseeing clinical research across various entities such as NHS trusts, clinical trial units, investigator sites, site networks, CROs, sponsors, and academic research organizations. It includes an array of modules that support trial management, electronic documentation for both trials and investigator sites, operations in pharmacies and laboratories, quality assurance, corrective and preventive actions (CAPA), along with the digital delegation of authority. This platform facilitates the seamless integration of regulated trial records and comprehensive audit trails, leading to improved efficiency in study operations. By harnessing Connected Intelligence, the software utilizes AI to pinpoint potential gaps and propose subsequent actions, with the stipulation that each recommendation must be validated by a designated user, thereby ensuring that customer data remains confidential and is not employed for AI model training. Hosted within the UK regions of Microsoft Azure, the AQ Platform is meticulously crafted to comply with ICH E6(R3) guidelines and meets the standards anticipated by the MHRA for Good Clinical Practice inspections. Furthermore, AQ Trials has received the NHS DSPT Standards Met (2026) designation and holds Cyber Essentials certification, underscoring its dedication to security and adherence to regulatory requirements. Created by physicians specializing in Phase 1 trials, the system offers the flexibility of individual module deployment, and it has been actively implemented in NHS operations since 2020, which highlights its effectiveness and reliability in practical clinical environments. The platform is continuously being enhanced based on user feedback, ensuring it adapts to the evolving demands of clinical research while maintaining high standards of performance and user satisfaction. As a result, it stands as a robust solution in the ever-changing landscape of clinical trial management.